MMR Vaccine and Viremia

Understanding Vaccine-Induced Viremia

The MMR vaccine contains live attenuated strains of measles, mumps, and rubella viruses that must replicate to produce an immune response, resulting in low-level viremia, which is generally asymptomatic in immunocompetent individuals, though approximately 5% develop transient measles-like rash 7-10 days after vaccination due to this viral replication 1, 2
The MMR vaccine is associated with mild fever in about 5% of children, typically occurring 7-12 days post-vaccination when viral replication peaks 2

Fever and rash appear 7-12 days after vaccination, coinciding with peak viral replication and immune response, and are mild, brief, and represent normal vaccine response rather than adverse events requiring intervention 2, 3
Transient lymphadenopathy sometimes occurs following rubella component replication, and parotitis has been reported rarely from mumps component replication 2, 3

Enhanced viral replication occurs in severely immunocompromised individuals due to inadequate immune surveillance, potentially leading to disseminated vaccine-strain infection, and vaccine-associated measles deaths have been documented in severely immunocompromised patients 4
The Centers for Disease Control and Prevention recommends that MMR is absolutely contraindicated in patients with severe immunocompromise, defined as: congenital immunodeficiency, severe HIV immunosuppression, active malignancy, chemotherapy, or high-dose corticosteroids 4

The American Academy of Pediatrics notes that vaccine virus transmission is extraordinarily rare, despite viremia occurring in vaccinees, and transmission of MMR vaccine strains from vaccinated individuals to contacts has been documented only in exceptional circumstances 4
The World Health Organization states that the viremia from MMR vaccine does NOT cause subacute sclerosing panencephalitis (SSPE), encephalopathy, or permanent neurological damage in immunocompetent hosts, and does not cause Crohn's disease or inflammatory bowel disease 2, 3, 4

The Centers for Disease Control and Prevention recommends that the controlled viremia induced by MMR vaccination carries vastly lower risks than natural infection, including lower rates of encephalopathy, subacute sclerosing panencephalitis, and idiopathic thrombocytopenic purpura 2, 3, 4

Local rash at the injection site occurs in a small percentage of recipients, particularly with MMRV formulations, with an incidence of approximately 2.3% of first-dose recipients, according to the Centers for Disease Control and Prevention (CDC) 5
Non-specific rash occurring anywhere on the body has been documented in clinical trials, appearing in approximately 4% of vaccine recipients within 43 days of vaccination, as reported by the CDC 5, 6

Urticaria (hives) after MMR vaccination is a rare hypersensitivity reaction, with anaphylactic reactions being extremely rare at less than 1 case per million doses, as stated by the CDC 7
The gelatin component is the most frequently associated allergen with reactions after MMR vaccination, and extreme caution should be exercised when administering MMR to persons with a history of anaphylactic reaction to gelatin or gelatin-containing products, according to the CDC 8

Egg allergy is NOT a contraindication for MMR vaccine, as anaphylactic reactions are not associated with egg antigens but with other vaccine components like gelatin, as reported by the CDC 7
Contact dermatitis to neomycin is NOT a contraindication to MMR vaccination, but persons with anaphylactic reactions to neomycin should not receive the vaccine, as stated by the CDC 8